DAWN vs. SPRY

Last updated Jun 3, 2026

DAWN (Day One Biopharmaceuticals, Inc.) and SPRY (Silverback Therapeutics Inc) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. At a 0.27 correlation, their price movements are largely independent.

Performance

DAWN vs. SPRY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Day One Biopharmaceuticals, Inc. (DAWN) and Silverback Therapeutics Inc (SPRY). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

DAWN

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

SPRY

• 1D: -5.62%
• 1M: 3.97%
• YTD: -23.61%
• 6M: -1.55%
• 1Y: -38.45%
• 3Y*: 7.12%
• 5Y*: -21.09%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

DAWN vs. SPRY - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
DAWN Day One Biopharmaceuticals, Inc.	131.01%	-26.44%	-13.22%	-32.16%	27.72%	-34.92%
SPRY Silverback Therapeutics Inc	-23.61%	10.43%	92.52%	-35.76%	28.08%	-75.20%

Correlation

The correlation between DAWN and SPRY is 0.22, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.22
Correlation (3Y) Calculated over the trailing 3-year period	0.31
Correlation (5Y) Calculated over the trailing 5-year period	0.27
Correlation (All Time) Calculated using the full available price history since May 28, 2021	0.27

Fundamentals

EPS DAWN : -$1.47 SPRY : -$2.00
PS Ratio DAWN : 16.63 SPRY : 8.88
Total Revenue (TTM) DAWN : $133.67M SPRY : $98.99M
Gross Profit (TTM) DAWN : $119.56M SPRY : $59.93M
EBITDA (TTM) DAWN : -$141.73M SPRY : -$194.60M

Return for Risk

DAWN vs. SPRY — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SPRY

SPRY Risk / Return Rank: 19
SPRY Sharpe Ratio Rank: 15
SPRY Sortino Ratio Rank: 18
SPRY Omega Ratio Rank: 19
SPRY Calmar Ratio Rank: 19
SPRY Martin Ratio Rank: 23

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

DAWN vs. SPRY - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Day One Biopharmaceuticals, Inc. (DAWN) and Silverback Therapeutics Inc (SPRY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	DAWN	SPRY	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	-0.58	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	-0.26	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	-0.21	—

Drawdowns

Drawdown Indicators

	DAWN	SPRY	Difference
Max Drawdown Largest peak-to-trough decline	—	-95.20%	—
Max Drawdown (1Y) Largest decline over 1 year	—	-63.32%	—
Max Drawdown (3Y) Largest decline over 3 years	—	-63.32%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-91.77%	—
Current Drawdown Current decline from peak	—	-85.27%	—
Average Drawdown Average peak-to-trough decline	—	-78.24%	—
Ulcer Index Depth and duration of drawdowns from previous peaks	—	43.04%	—

Volatility

Volatility by Period

	DAWN	SPRY	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	21.70%	—
Volatility (6M) Calculated over the trailing 6-month period	—	46.95%	—
Volatility (1Y) Calculated over the trailing 1-year period	—	66.83%	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	—	80.09%	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	—	80.85%	—

Dividends

DAWN vs. SPRY - Dividend Comparison

Neither DAWN nor SPRY has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both DAWN and SPRY in my portfolio?

DAWN and SPRY have a correlation of 0.22, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.